Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: Evidence for epithelialmesenchymal transition

Histopathology

Volumn 55, Issue 1, 2009, Pages 91-101

  Stewart, Colin J R ^a   Little, Leonie ^a,b  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Carcinoma; EMT; Endometrial; Immunohistochemistry; Invasion; MELF

Indexed keywords

CYTOKERATIN; CYTOKERATIN AE1; CYTOKERATIN AE3; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CADHERINS; CELL DIFFERENTIATION; ENDOMETRIAL NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERMEDIATE FILAMENTS; KERATIN-7; MESODERM; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 68049140928     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03327.x     Document Type: Article

References (45)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005 366 491 505.
2. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 2008 111 436 447.
3. Prat J. Prognostic parameters of endometrial carcinoma. Hum. Pathol. 2004 35 649 662.
4. Snyder MJ, Bentley R, Robboy SJ. Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int. J. Gynecol. Pathol. 2006 25 155 160.
5. Ali A, Black D, Soslow RA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int. J. Gynecol. Pathol. 2007 26 115 123.
6. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. Am. J. Surg. Pathol. 1988 12 754 758.
7. Landry D, Mai KT, Senterman MK et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology 2003 42 77 82.
8. Longacre T, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am. J. Surg. Pathol. 1999 23 69 78.
9. Clement PB, Young RH. Atlas of gynecologic surgical pathology, 2nd edn. Philadelphia : Elsevier Saunders, 2008.
10. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003 22 324 333.
11. Stewart CJR, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009 41 471 476.
12. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007 39 305 318.
13. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol. Med. 2007 13 535 541.
14. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002 2 442 454.
15. Hugo H, Ackland ML, Blick T et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 2007 213 374 383.
16. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007 50 151 162.
17. Brabletz T, Hlubek F, Spaderna S et al. Invasion and metastases in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs 2005 179 56 65.
18. Blechschmidt K, Kremmer E, Hollweck R et al. The E-cadherin repressor Snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn. Mol. Pathol. 2007 16 222 228.
19. Shih H-C, Shiozawa T, Miyamoto T et al. Immunohistochemical expression of E-cadherin and β-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear β-catenin expression. Anticancer Res. 2004 24 3843 3850.
20. Scholten AN, Aliredjo R, Creutzberg CL, Smit VTHBM. Combined E-cadherin, α-catenin, and β-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int. J. Gynecol. Cancer 2006 16 1379 1385.
21. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet. Gynecol. 2002 100 1290 1295.
22. Saito T, Nishimura M, Yamasaki H, Kudo R. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferentiation and myometrial invasion in endometrial carcinoma. Cancer 2003 97 1002 1009.
23. Sakuragi N, Nishiya M, Ikeda K et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol. Oncol. 1994 53 183 189.
24. Moreno-Bueno G, Hardisson D, Sarrio D et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J. Pathol. 2003 199 471 478.
25. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J. Clin. Oncol. 2004 22 1242 1252.
26. Mell LK, Meyer JJ, Tretiakova M et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin. Cancer Res. 2004 10 5546 5553.
27. Leblanc M, Poncelet C, Soriano D et al. Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch. 2001 438 78 85.
28. Abal M, Llaurado M, Doll A et al. Molecular determinants of invasion in endometrial cancer. Clin. Transl. Oncol. 2007 9 272 277.
29. Kyo S, Sakaguchi J, Ohno S et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum. Pathol. 2006 37 431 438.
30. Kang Y, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004 118 277 279.
31. Horree N, van Diest PJ, Sie-Go DMDS, Heintz APM. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum. Pathol. 2007 38 1232 1238.
32. Kirchner T, Muller S, Hattori T et al. Metaplasia, intraepithelial neoplasia and early cancer of the stomach are related to dedifferentiated epithelial cells defined by cytokeratin-7 expression in gastritis. Virchows Arch. 2001 439 512 522.
33. Stenling R, Lindberg J, Rutegard J, Palmqvist R. Altered expression of CK7 and CK20 in preneoplastic and neoplastic lesions in ulcerative colitis. APMIS 2007 115 1219 1226.
34. Zaino RJ. The fruits of our labors: distinguishing endometrial from endocervical adenocarcinoma. Int. J. Gynecol. Pathol. 2002 21 1 3.
35. Dabbs DJ, Geisinger KR, Norris HT. Intermediate filaments in endometrial and endocervical carcinomas: the diagnostic utility of vimentin patterns. Am. J. Surg. Pathol. 1986 10 568 576.
36. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int. J. Gynecol. Pathol. 2002 21 4 10.
37. Papadopoulos N, Kotini A, Cheva A et al. Immunohistochemical expression of vimentin and secretory component antigens in endometrial hyperplasia and neoplasia. Eur. J. Gynaecol. Oncol. 2002 23 411 414. (Pubitemid 35364668)
38. Kamoi S, Al Juboury MI, Akin MR, Silverberg SG. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int. J. Gynecol. Pathol. 2002 21 217 223.
39. Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006 19 1091 1100.
40. Ioachin E. Immunohistochemical tumour markers in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 2005 26 363 371.
41. Fujita N, Jaye DL, Kajita M et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003 113 207 219.
42. Dandachi N, Hauser-Kronberger C, More E et al. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J. Pathol. 2001 193 181 189.
43. Hanekamp EE, Gielen SCJP, De Ruiter PE et al. Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins. J. Soc. Gynecol. Investig. 2005 12 278 284.
44. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002 62 881 886.
45. Hanekamp EE, Kuhne ECM, Smid-Koopman E et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur. J. Cancer 2002 38 S71 S72.